Earnings call transcript: SQM's Q2 2025 results exceed expectations amid stock dip

Sociedad Quimica y Minera de Chile SA (SQM) reported Q2 2025 EPS of $0.79 and revenue of $2.08 billion, significantly surpassing analyst forecasts by 36.21% and 92.59% respectively. Despite these strong financial results, the stock declined 4.53% in premarket trading, reflecting broader market volatility and sector-specific challenges. While overall revenue decreased year-on-year due to lower lithium prices, profitability was sustained by the robust performance of its iodine segment, which contributed over 50% of gross profit. The company anticipates increased lithium sales volumes for 2025 amid improving lithium prices and demand, and expects its strategic partnership with Codelco to finalize by Q4, with InvestingPro assessing SQM as undervalued.

Analysis

Sociedad Quimica y Minera de Chile (SQM) reported a significant outperformance for Q2 2025, with EPS of $0.79 and revenue of $2.08 billion, beating forecasts by 36% and 93% respectively. Despite these strong results, the stock experienced a 4.53% decline in premarket trading, indicating that investor focus may be on broader sector volatility and the year-over-year revenue decline of over 3% caused by lower lithium prices. The company's diversified business model proved its resilience, as the iodine segment was the primary profit driver, contributing over 50% of total gross profit with an exceptional 57% gross margin. This performance effectively cushioned the impact of lithium market weakness. Looking forward, the outlook is positive, with management noting improving lithium prices and demand from China and Europe, and subsequently guiding for a minimum 10% increase in Chilean lithium sales volume for 2025. Key strategic projects are advancing, with the Mt. Holland refinery now complete and the pivotal Codelco partnership expected to be finalized by Q4 2025, which should remove a significant overhang for the stock. Based on InvestingPro's analysis, the company maintains strong financial health and appears undervalued, a view supported by a consensus "Buy" recommendation from analysts.

Key Decisions for Investors

• Investors should analyze the disconnect between the 4.53% premarket stock decline and the substantial Q2 earnings outperformance, as the negative reaction appears more tied to sector volatility than to the company's robust fundamentals and positive guidance.
• Key near-term catalysts to monitor are the finalization of the Codelco partnership, expected by Q4 2025, and the successful ramp-up of the Mt. Holland refinery, both of which are critical for de-risking the equity story and realizing future growth.
• Given the improving lithium market dynamics, strong forward guidance on sales volumes, and the exceptional profitability of the iodine segment, the current valuation, which is assessed as undervalued by some metrics, may present a compelling entry point for long-term investors.